38 results about "Acinetobacter infections" patented technology

The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against A. baumannii infection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization against A. baumannii infection. The compositions and methods of the invention are useful for preventing or treating A. baumannii infections, including those caused by strains resistant to carbapenems and all other antibiotics except colistin or tigecycline, also referred to as extreme drug resistant (XDR) A. baumannii infections, and those resistant to every FDA approved antibiotic, also referred to as pan-drug resistant (PDR) A. baumannii infections.

The invention belongs to the field of biomedicine, and particularly relates to a compound containing cyclohydroxamic acid as well as a preparation method and an application of same. The structural general formula of the compound containing cyclohydroxamic acid is shown as the specification, wherein R is one of F, Cl, Br, I,-CH3, -OCH3, -SCH3, acetyl group and cyanate radical; R1 is H, -CH3, -(CH2)nCH3, a benzene ring and an aromatic ring that has any one of F, Cl, Br, I, O, OH, -CH3, -OCH3, and cyano group; wherein the n is an integer from 1 to 8; and R2 is one of a C1-C14 chain substituent group, hydrogen, allyl, alkenebutyl, benzyl, aromatic ring, and one of benzyl group and sulphonyl group having a substituent group. According to the compound, acinetobacter baumannii infection can be reduced by inhibiting a biological membrane, the occurrence probability of infectious diseases is reduced from the source, and side effects are few. The compound also has good exopolysaccharide inhibition capability and is non-toxic.

The invention discloses a method for screening drugs against pan-drug-resistant Acinetobacter baumannii by using Caenorhabditis elegans. First, a C. elegans-pan-drug-resistant Acinetobacter baumannii infection model for screening the efficacy of the composition was constructed, and the C. elegans had glp‑ 4;sek‑1 Double gene mutation; C. elegans-pandrug-resistant Acinetobacter baumannii co-culture medium consists of 20% BHI+5~20μM nalidixic acid+5~20μg / ml FeCl 3 ; The concentration of pan-resistant Acinetobacter baumannii is 1×10 6 ~1×10 9 CFU / mL; the duration of bacterial infection of C. elegans is 6-12 hours; the duration of drug treatment of infection model is 24-48 hours. The model can be used for rapid and high-throughput screening of the in vivo antibacterial activity of various compounds or drugs or compositions. Compared with the in vivo animal infection model, the model has the great advantages of low preparation cost, short cycle and simple operation. Compared with in vitro models, compounds with high toxicity in vivo, poor metabolism and low correlation between in vitro and in vivo can be screened out.